Zobrazeno 1 - 10
of 17
pro vyhledávání: '"Marilia Santini de Oliveira"'
Publikováno v:
RECIIS, Vol 2, Iss 2 (2008)
USA: Oxford University Press; 2004 ISBN: 978-0195176841
Externí odkaz:
https://doaj.org/article/a10bd7d48ce741689be42da65d938636
Publikováno v:
RECIIS, Vol 2, Iss 2, Pp 113-114 (2009)
Externí odkaz:
https://doaj.org/article/008ebb11dbde4a7fa0fd299055c88072
Autor:
Marilia Santini de Oliveira, Valdilea G. Veloso, Antonieta Medina-Lara, Raquel Brandini De Boni, Rodolfo Castro, Paula M. Luz, Livia Valentim Lopes, Sandra W. Cardoso, Luciane de Souza Velasque, Ruth Khalili Friedman, Beatriz Grinsztejn
Publikováno v:
Quality of Life Research. 28:1035-1045
To assess health-related quality of life (HRQoL) and its associated factors among people living with HIV/AIDS (PLWHA) in Rio de Janeiro, Brazil. A cross-sectional study including PLWHA receiving usual HIV-care at Instituto Nacional de Infectologia Ev
Autor:
Beatriz Grinsztejn, Elaine Sampaio Araujo, Marilia Santini de Oliveira, Luis Antonio Bastos Camacho, Ruth Khalili Friedman, José Henrique Pilotto, Ronaldo I. Moreira, Monica Derrico, Valdilea G. Veloso, Guilherme Amaral Calvet
Publikováno v:
Brazilian Journal of Infectious Diseases, Vol 18, Iss 3, Pp 252-260 (2014)
Brazilian Journal of Infectious Diseases, Volume: 18, Issue: 3, Pages: 252-260, Published: JUN 2014
Brazilian Journal of Infectious Diseases v.18 n.3 2014
Brazilian Journal of Infectious Diseases
Brazilian Society of Infectious Diseases (BSID)
instacron:BSID
Brazilian Journal of Infectious Diseases, Volume: 18, Issue: 3, Pages: 252-260, Published: JUN 2014
Brazilian Journal of Infectious Diseases v.18 n.3 2014
Brazilian Journal of Infectious Diseases
Brazilian Society of Infectious Diseases (BSID)
instacron:BSID
Objectives: To describe the access to the interventions for the prevention of Human Immunodeficiency Virus (HIV) mother to child transmission and mother to child transmission rates in the outskirts of Rio de Janeiro, from 1999 to 2009. Methods: This
Autor:
Joilson Xavier, Vagner Fonseca, Talita Adelino, Felipe C. M. Iani, Glauco C. Pereira, Myrian M. Duarte, Mauricio Lima, Emerson Castro, Carla Oliveira, Hegger Fritsch, Natalia Guimarães, Ludmila O. Lamounier, Fernanda Khouri Barreto, Camilo M. M. Braga de Oliveira, Crhistinne C. Maymone Gonçalves, Danielle Malta Lima, Elaine C. de Oliveira, Gislene G. de Castro Lichs, Iago Gomes, Janaina Mazaro, Janete T. N. Rodrigues, Jayra Abrantes, Jeová K. B. Colares, Kleber G. Luz, Luana Barbosa da Silva, Luiz Demarchi, Magaly C. B. Câmara, Marina C. S. Umaki Zardin, Rafaela Sabatini Mello Pinheiro, Rutilene Barbosa Souza, Simone K. Haddad, Stephanni Figueiredo da Silva, Svetoslav N. Slavov, Themis Rocha, Noelia Morel, Hector Chiparelli, Analía Burgueño, Victoria Bórmida, María N. Cortinas, Rosario S. Martín, Allan C. Pereira, Marcelo F. dos Santos, Walter André Júnior, Jairo Mendez Rico, Leticia Franco, Alexander Rosewell, Rodrigo F. do Carmo Said, Carlos F. C. de Albuquerque, Ethel L. Noia Maciel, Marília Santini de Oliveira, Rivaldo Venâncio da Cunha, Livia C. Vinhal Frutuoso, Ana M. B. de Filippis, Marta Giovanetti, Luiz Carlos Junior Alcantara
Publikováno v:
Viruses, Vol 16, Iss 1, p 23 (2023)
The emergence and continued geographic expansion of arboviruses and the growing number of infected people have highlighted the need to develop and improve multiplex methods for rapid and specific detection of pathogens. Sequencing technologies are pr
Externí odkaz:
https://doaj.org/article/34f7f735dc114ed5992ec69c2c0fc9d0
Publikováno v:
Future Virology. 6:561-570
Lopinavir/ritonavir approval for use in antiretroviral treatment 10 years ago was very important for the recognition of boosted protease inhibitor (PI)-based therapy as an attractive option for first-line therapy. Being coformulated with ritonavir an
Publikováno v:
HIV Therapy. 4:531-542
In the last 5 years there have been important achievements in the field of HIV therapy with the availability of new classes of antiretrovirals together with a new generation of old classes. Among them, the development of raltegravir, the first commer
Autor:
Jorge Eurico Ribeiro, Marilia Santini de Oliveira, Michael Norton, José Cláudio Faulhaber, José Henrique Pilotto, Roberto Zajdenverg, Monica Merçon, Mauro Schechter, Estevão Portela Nunes
Publikováno v:
HIV clinical trials. 10(6)
Long-term adverse events and expenses associated with HAART have led to an interest in simplified therapy. Lopinavir/ritonavir monotherapy is attractive due to its potency and high genetic barrier.This is a 96-week, open-label, randomized study to as